Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Cancers (Basel) ; 12(8)2020 Jul 29.
Article in English | MEDLINE | ID: mdl-32751137

ABSTRACT

Despite the progress during the last decade, patients with advanced gastric and esophageal cancers still have poor prognosis. Finding optimal therapeutic strategies represents an unmet need in this field. Several prognostic and predictive factors have been evaluated and may guide clinicians in choosing a tailored treatment. Data from large studies investigating the role of immunotherapy in gastrointestinal cancers are promising but further investigations are necessary to better select those patients who can mostly benefit from these novel therapies. This review will focus on the treatment of metastatic esophageal and gastric cancer. We will review the standard of care and the role of novel therapies such as immunotherapies and CAR-T. Moreover, we will focus on the analysis of potential predictive biomarkers such as Modify as: Microsatellite Instability (MSI) and PD-L1, which may lead to treatment personalization and improved treatment outcomes. A multidisciplinary point of view is mandatory to generate an integrated approach to properly exploit these novel antiproliferative agents.

3.
Cancer ; 120(4): 513-20, 2014 Feb 15.
Article in English | MEDLINE | ID: mdl-24258498

ABSTRACT

BACKGROUND: Polycythemia vera (PV) is a myeloproliferative neoplasm associated with somatic gain-of-function mutations of Janus kinase-2 (JAK2). Therapeutic options are limited in patients with advanced disease. Ruxolitinib, an oral JAK1/JAK2 inhibitor, is active in preclinical models of PV. The long-term efficacy and safety of ruxolitinib in patients with advanced PV who are refractory or intolerant to hydroxyurea were studied in a phase 2 trial. METHODS: Response was assessed using modified European LeukemiaNet criteria, which included a reduction in hematocrit to <45% without phlebotomy, resolution of palpable splenomegaly, normalization of white blood cell and platelet counts, and reduction in PV-associated symptoms. RESULTS: Thirty-four patients received ruxolitinib for a median of 152 weeks (range, 31 weeks-177 weeks) or 35.0 months (range, 7.1 months-40.7 months). Hematocrit <45% without phlebotomy was achieved in 97% of patients by week 24.Only 1 patient required a phlebotomy after week 4. Among patients with palpable splenomegaly at baseline, 44% and 63%, respectively, achieved nonpalpable spleen measurements at weeks 24 and 144. Clinically meaningful improvements in pruritus, night sweats, and bone pain were observed within 4 weeks of the initiation of therapy and maintained with continued treatment. Ruxolitinib treatment also reduced elevated levels of inflammatory cytokines and granulocyte activation. Thrombocytopenia and anemia were the most common adverse events.Thrombocytopenia of grade 3 or anemia of grade 3 (according to National Cancer Institute Common Terminology Criteria for Adverse Events,version 3.0) occurred in 3 patients each (9%) (1 patient had both) and were managed with dose modification. CONCLUSIONS: Ruxolitinib was generally well tolerated and provided rapid and durable clinical benefits in patients with advanced PV who were refractory or intolerant to hydroxyurea.


Subject(s)
Janus Kinase 1/genetics , Janus Kinase 2/genetics , Polycythemia Vera/drug therapy , Pyrazoles/administration & dosage , Adult , Aged , Aged, 80 and over , Anemia/blood , Anemia/chemically induced , Anemia/pathology , Contraindications , Drug-Related Side Effects and Adverse Reactions/classification , Drug-Related Side Effects and Adverse Reactions/pathology , Female , Granulocytes/pathology , Hematocrit , Humans , Hydroxyurea/adverse effects , Janus Kinase 1/antagonists & inhibitors , Janus Kinase 2/antagonists & inhibitors , Male , Middle Aged , Nitriles , Polycythemia Vera/blood , Polycythemia Vera/pathology , Pyrimidines , Thrombocytopenia/blood , Thrombocytopenia/chemically induced , Thrombocytopenia/pathology , Young Adult
4.
Cancer Biol Ther ; 13(9): 702-11, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22684580

ABSTRACT

Invariant natural killer T (iNKT) cells are a distinct subset of human T cells, which expresses an invariant T cell receptor Vα24 Jα18 and recognizes glycolipid antigens in the context of CD1d molecules. iNKT cells exert pivotal regulatory roles in many immune responses, including antitumor immune responses. Alterations in iNKT cell frequency, phenotype, and activation state have been reported in cancer patients. No data are available on the iNKT cells in malignant pleural mesothelioma (MPM), a rare, but very aggressive, malignancy of the pleura with a very poor prognosis. Here, we studied the frequency, phenotype, and cytokine profile of circulating iNKT cells in MPM patients, and correlated results with tumor histological types (epithelioid, sarcomatoid, biphasic) and clinical stages (I-III). We found that the iNKT cell frequency was significantly increased in MPM patients with epithelioid and sarcomatoid types in comparison with healthy volunteers (HV); only three biphasic mesotheliomas were available in this study, thus no conclusions can be drawn for this MPM type. The increased frequency significantly correlates with the clinical stage of tumor with the highest value at the stage III in both epithelioid and sarcomatoid subtypes. According to the histological types, we measured changes in the frequencies of CD4⁺ CD8⁺ (DP) and CD4⁻CD8⁻ (DN), but not in the cytokine profiles (IFN-γ/IL-4 expression). These results demonstrate that the frequency of iNKT cells is increased in MPM patients and that this increase correlates with MPM type and stage.


Subject(s)
Mesothelioma/pathology , Natural Killer T-Cells/pathology , Pleural Neoplasms/pathology , Adult , Aged , Aged, 80 and over , Antigens, CD/metabolism , Case-Control Studies , Female , Humans , Interferon-gamma/blood , Interferon-gamma/metabolism , Interleukin-4/blood , Interleukin-4/metabolism , Lymphocyte Count , Male , Mesothelioma/blood , Mesothelioma/immunology , Middle Aged , Natural Killer T-Cells/metabolism , Neoplasm Staging , Phenotype , Pleural Neoplasms/blood , Pleural Neoplasms/immunology
5.
Blood ; 118(8): 2069-76, 2011 Aug 25.
Article in English | MEDLINE | ID: mdl-21725052

ABSTRACT

In addition to dysregulated JAK/STAT signaling, activation of the AKT/mTOR pathway occurs in myelofibrosis, a myeloproliferative neoplasm with no approved therapies. We conducted a phase 1/2 study with everolimus, an mTOR inhibitor, in 39 high- or intermediate-risk primary or postpolycythemia vera/postessential thrombocythemia myelofibrosis subjects. Responses were evaluated in 30 patients of phase 2. No dose-limiting toxicity was observed in phase 1 up to 10 mg/d. When this dose was used in phase 2, grade ≥ 3 toxicities were infrequent; the commonest toxicity was grade 1-2 stomatitis. Rapid and sustained splenomegaly reduction of > 50% and > 30% occurred in 20% and 44% of subjects, respectively. A total of 69% and 80% experienced complete resolution of systemic symptoms and pruritus. Response in leukocytosis, anemia, and thrombocytosis occurred in 15%-25%. Clinical responses were not associated with reduced JAK2V617F burden, circulating CD34(+) cells, or cytokine levels, whereas CCDN1 mRNA and phospho-p70S6K level, known targets of mTOR, and WT1 mRNA were identified as possible biomarkers associated with response. Response rate was 60% when European Network for Myelofibrosis criteria were used (8 major, 7 moderate, 3 minor responses) or 23% when IWG-MRT criteria (1 partial response, 6 clinical improvements) were used. These results provide proof-of-concept that targeting mTOR pathway in myelofibrosis may be clinically relevant.


Subject(s)
Primary Myelofibrosis/drug therapy , Protein Kinase Inhibitors/therapeutic use , Sirolimus/analogs & derivatives , TOR Serine-Threonine Kinases/antagonists & inhibitors , Adult , Aged , Cyclin D1/genetics , Everolimus , Female , Humans , Janus Kinase 2/genetics , Male , Middle Aged , Mutation , Polycythemia Vera/complications , Primary Myelofibrosis/enzymology , Primary Myelofibrosis/etiology , Protein Kinase Inhibitors/administration & dosage , Protein Kinase Inhibitors/adverse effects , RNA, Messenger/genetics , RNA, Messenger/metabolism , Receptors, Thrombopoietin/genetics , Signal Transduction/drug effects , Sirolimus/administration & dosage , Sirolimus/adverse effects , Sirolimus/therapeutic use , Thrombocythemia, Essential/complications , Treatment Outcome , WT1 Proteins/genetics
6.
Tumori ; 97(3): 362-6, 2011.
Article in English | MEDLINE | ID: mdl-21789017

ABSTRACT

AIMS AND BACKGROUND: Palonosetron, a unique second-generation 5-HT3 receptor antagonist, has been demonstrated to control emesis related to chemotherapy-induced nausea and vomiting (CINV). The aim of this study was to evaluate the efficacy and tolerability of palonosetron followed by a single dose of dexamethasone in patients with breast cancer (BC) or colorectal cancer (CRC) receiving moderate emetogenic chemotherapy (MEC). METHODS AND STUDY DESIGN: Chemotherapy-naive BC and CRC patients were given MEC as adjuvant or first-line treatment. Palonosetron (0.25 mg IV) and dexamethasone (8 mg IV) were administered before chemotherapy on day 1. The primary endpoint was complete response (CR; no vomiting and no use of rescue medication) during the overall study period (days 1-5). The antiemetic response was evaluated during the acute (day 1) and delayed (days 2-5) phases. RESULTS: Sixty-eight patients were enrolled (median age 61 years, 56 females; BC = 40, CRC = 28). CR was observed in 46 of 68 patients (67.6%), while CR during the acute and delayed phases was 75.0% in each cancer group. The antiemetic regimen was well tolerated. CONCLUSIONS: A single administration of palonosetron and dexamethasone on day 1 in BC and CRC patients adequately controls CINV during the entire period of emetic risk.


Subject(s)
Antiemetics/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Breast Neoplasms/drug therapy , Colorectal Neoplasms/drug therapy , Dexamethasone/administration & dosage , Isoquinolines/administration & dosage , Nausea/prevention & control , Quinuclidines/administration & dosage , Vomiting/prevention & control , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Breast Neoplasms/pathology , Colorectal Neoplasms/pathology , Female , Humans , Male , Middle Aged , Nausea/chemically induced , Palonosetron , Prospective Studies , Serotonin Antagonists/administration & dosage , Treatment Outcome , Vomiting/chemically induced
8.
Br J Haematol ; 150(4): 446-55, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20560970

ABSTRACT

A phase II A study was conducted to evaluate the safety and efficacy of Givinostat, a novel Histone-Deacetylases inhibitor, in patients with Polycythaemia Vera (PV, n = 12), Essential Thrombocythaemia (ET, n = 1) and Myelofibrosis (n = 16), bearing the JAK2V617F mutation. The study was approved by the local ethics committees and all human participants gave written informed consent. Givinostat was given orally for 24 weeks at a starting dose of 50 mg twice daily. The median treatment duration was 20 weeks. Reasons for treatment discontinuation were disease progression (n = 6), grade 2 thrombocytopenia (n = 1), psychiatric symptoms (n = 1) and withdrawn consent (n = 2). A dose reduction was applied in 10 patients while a temporary interruption occurred in 15. Among 13 PV/ET patients, 1 complete, 6 partial and 4 no responses were documented at study end while 2 patients went off-study, prematurely. Three major responses were registered among 16 MF patients. Pruritus disappeared in most patients and reduction of splenomegaly was observed in 75% of PV/ET and 38% of MF patients. Reverse transcription polymerase chain reaction identified a trend to reduction of the JAK2V617F allele burden. Givinostat was well tolerated and could induce haematological response in most PV and some MF patients.


Subject(s)
Histone Deacetylase Inhibitors/adverse effects , Hydroxamic Acids/adverse effects , Myeloproliferative Disorders/drug therapy , Adult , Aged , Drug Administration Schedule , Female , Histone Deacetylase Inhibitors/administration & dosage , Histone Deacetylase Inhibitors/therapeutic use , Humans , Hydroxamic Acids/administration & dosage , Hydroxamic Acids/therapeutic use , Janus Kinase 2/genetics , Male , Middle Aged , Myeloproliferative Disorders/genetics , Pilot Projects , Polycythemia Vera/drug therapy , Polycythemia Vera/genetics , Primary Myelofibrosis/drug therapy , Primary Myelofibrosis/genetics , Thrombocythemia, Essential/drug therapy , Thrombocythemia, Essential/genetics , Treatment Outcome
9.
Blood ; 110(12): 4030-6, 2007 Dec 01.
Article in English | MEDLINE | ID: mdl-17712047

ABSTRACT

Few investigators have evaluated the usefulness of the JAK2 V617F mutation for explaining the phenotypic variations and for predicting the risk of major clinical events in primary myelofibrosis (PMF). In a transversal survey we assayed by allele-specific polymerase chain reaction (PCR) the JAK2 V617F mutational status in 304 patients with PMF. Multiple DNA samples were collected prospectively from 64 patients, and a highly sensitive quantitative PCR was used as a confirmatory test. In a longitudinal prospective study we determined the progression rate to clinically relevant outcomes in 174 patients who had JAK2 mutation determined at diagnosis. JAK2 V617F was identified in 63.4% of patients. None of the V617F-negative patients who were sequentially genotyped progressed to become V617F positive, whereas progression rate from heterozygous to homozygous mutation was 10 per 100 patient-years. JAK2 V617F mutation contributed to hemoglobin, aquagenic pruritus, and platelet count variability, whereas homozygous mutation was independently associated with higher white blood cell count, larger spleen size, and greater need for cytoreductive therapies. Adjusting for conventional risk factors, V617F mutation independently predicted the evolution toward large splenomegaly, need of splenectomy, and leukemic transformation. We conclude that JAK2 V617F genotype should be considered in any future risk stratification of patients with PMF.


Subject(s)
Cell Transformation, Neoplastic/genetics , Janus Kinase 2/genetics , Leukemia/genetics , Mutation, Missense , Primary Myelofibrosis/genetics , Splenomegaly/genetics , Adult , Alleles , Amino Acid Substitution , Female , Humans , Leukemia/diagnosis , Leukemia/etiology , Loss of Heterozygosity/genetics , Male , Middle Aged , Polymerase Chain Reaction , Primary Myelofibrosis/complications , Primary Myelofibrosis/diagnosis , Prospective Studies , Retrospective Studies , Risk Factors , Splenomegaly/diagnosis , Splenomegaly/etiology , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...